The four frontier-lab CEOs put their names on a single biosecurity ask to Congress
Dario Amodei, Sam Altman, Demis Hassabis and Mustafa Suleyman signed a joint open letter on June 5 urging Congress to make synthetic-DNA screening and order recordkeeping mandatory for every nucleic-acid synthesis vendor operating in the United States. The letter, organized by the Foundation for American Innovation and the Institute for Progress, argues that frontier AI has dropped the expertise barrier for designing biological weapons low enough that the gene-synthesis supply chain is now the binding constraint. Anthropic, OpenAI, Google DeepMind and Microsoft AI together account for the labs whose models the UK AISI flagged for expert-level biosecurity uplift in its spring 2026 Mythos and GPT-5.5-Cyber evaluations.
Fortune / Foundation for American Innovation · 2026-06-05 · Source ↗ ·
The four frontier-lab CEOs put their names on a single biosecurity ask to Congress
Dario Amodei, Sam Altman, Demis Hassabis and Mustafa Suleyman signed a joint open letter on June 5 urging Congress to make synthetic-DNA screening and order recordkeeping mandatory for every nucleic-acid synthesis vendor operating in the United States. The letter, organized by the Foundation for American Innovation and the Institute for Progress, argues that frontier AI has dropped the expertise barrier for designing biological weapons low enough that the gene-synthesis supply chain is now the binding constraint. Anthropic, OpenAI, Google DeepMind and Microsoft AI together account for the labs whose models the UK AISI flagged for expert-level biosecurity uplift in its spring 2026 Mythos and GPT-5.5-Cyber evaluations.
Fortune / Foundation for American Innovation · 2026-06-05 · Source ↗ ·
The joint open letter, titled "An Open Letter in Support of Mandatory Nucleic Acid Synthesis Screening and Recordkeeping," went up on the Foundation for American Innovation site on the evening of June 5 with the four signatures attached. Fortune, NPR, Interesting Engineering and CryptoBriefing all filed parallel write-ups within hours. The letter asks Congress to require every company that sells synthetic DNA and RNA in the United States to screen orders against pathogen and toxin sequence databases before fulfilling them, and to keep records of order specifications and customer identity so that federal biosecurity investigators can trace a misuse incident back through the supply chain.
The Foundation for American Innovation, a center-right tech-policy think tank, and the Institute for Progress, a nonpartisan science-policy group, organized the document. They circulated drafts privately for several weeks before the four labs signed. Anthropic, OpenAI, Google DeepMind and Microsoft AI represent the labs whose top models the UK AI Security Institute flagged earlier this year as having crossed expert-level biosecurity uplift thresholds during evaluation. Anthropic's Mythos preview scored 73 percent on the AISI's expert-level offensive-security evaluations in April; OpenAI's GPT-5.5-Cyber, which the company extended to EU government cybersecurity teams on June 5, is the parallel safety-vetted release on the OpenAI side.
What the letter actually asks
Two specific things. First, that any vendor synthesizing nucleic acids for commercial sale to US customers must run incoming orders against curated screening databases of pathogen and toxin sequences. The current US standard, the 2010 HHS Guidance, is voluntary. The four labs want it to be mandatory and enforceable by federal regulators. Second, that vendors must keep records of order specifications and customer identity for an unspecified retention period, so that if a biosecurity incident traces back to a specific synthetic-DNA order, federal investigators can identify the customer.
"AI is rapidly eroding the technical barriers that previously kept biological weapons design out of reach. Mandatory biosecurity screening at the gene-synthesis supply chain is the most tractable lever Congress can pull this year." — excerpt from the joint letter
Why these four CEOs at once
The biosecurity ask is the first policy point on which Amodei, Altman, Hassabis and Suleyman have publicly aligned without dissent. Amodei has been the loudest of the four on biosecurity for two years; his Senate testimony last August warned that frontier models could compress what was a multi-year, PhD-level skill stack down to days of guided work. The OpenAI signature is more politically loaded because the company has spent the past year arguing for voluntary review under the June 2 Trump executive order; signing onto a mandatory-screening ask on a different node of the supply chain lets the company support biosecurity controls without conceding ground on model licensing.
Hassabis brings the credibility of Google DeepMind's protein-design work through Isomorphic Labs, which now manages 17 active drug-development programs and is targeting clinical trials by year-end. Suleyman's signature lands four days after Microsoft Build, where MAI-Thinking-1 and MAI-Code-1-Flash signaled the company's move toward its own frontier-model stack. Microsoft AI signing on means the letter is not a closed-AI-company-versus-closed-AI-company artifact; it is a frontier-lab consensus.
What this means for the policy fight
The June 2 Trump executive order on AI explicitly prohibited federal preemption of state AI laws on biosecurity and child-safety topics. The four signatories are therefore asking Congress to legislate a federal floor on biosecurity that the executive branch's policy direction effectively leaves room for. The Foundation for American Innovation's involvement matters: FAI has close working relationships with House Republicans on the AI working group, including Jay Obernolte, whose June 4 Great American AI Act draft included a three-year preemption of state AI laws but exempted biosecurity. The letter is functionally a request that the Great American AI Act package screening mandates and recordkeeping into the same vehicle.
The pushback is concrete. Biotech industry groups have historically argued that mandatory screening would slow gene-synthesis turnaround times from days to weeks, hurting academic research. Privacy advocates have raised concerns about customer-record retention at a stage in the supply chain where some orders are for legitimate dual-use research. The Foundation for American Innovation said the letter explicitly leaves the customer-record retention period to Congress. The four CEOs did not commit to a specific implementation timeline; the letter's framing is "this calendar year." Markup of the Great American AI Act draft begins June 17 in the House AI Task Force.